“These devices are currently experiencing global supply pressure due to a disruption in the supply of one of their components”announced the National Medicines Safety Agency (ANSM) in a press release.
These are tests marketed by the Finnish group PerkinElmer and which aim to detect the risks of Down syndrome in the fetus during the first and second trimester of pregnancy.
This announcement comes in a context where shortages are hitting more and more medicines in France and internationally.
According to the ANSM, PerkinElmer assured that these supply difficulties would not have any concrete consequences, the group saying it was able to “cover global needs” up to one “back to normal” expected in 2024.
Nevertheless, the drug agency says it is looking “d’alternatives” to guarantee access to screening, one of the most common among pregnant women.
“We are monitoring the development of the situation as closely as possible in order to reduce its potential impact”says the ANSM, which does not specify what proportion these devices represent in the context of screening for Down syndrome in France.
“We have approached the Ministry of Health and Prevention and the Biomedicine Agency, in order to share information and possible solutions”she concludes.
